tetano
Editor, Senior Moderator
China CDC Wkly
. 2023 Apr 28;5(17):369-373.
doi: 10.46234/ccdcw2023.070. Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms - China, December 2022-February 2023
Di Fu[SUP] 1 [/SUP], Guanhao He[SUP] 2 3 [/SUP], Huanlong Li[SUP] 4 [/SUP], Haomin Tan[SUP] 1 3 [/SUP], Xiaohui Ji[SUP] 1 3 [/SUP], Ziqiang Lin[SUP] 1 3 [/SUP], Jianxiong Hu[SUP] 1 3 [/SUP], Tao Liu[SUP] 1 3 [/SUP], Jianpeng Xiao[SUP] 5 [/SUP], Xiaofeng Liang[SUP] 2 3 [/SUP], Wenjun Ma[SUP] 1 3 [/SUP]
Affiliations
What is already known about this topic?: A considerable percentage of the population has received both primary and booster vaccinations, which could potentially provide protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infections and related symptoms.
What is added by this report?: The self-reported infection rate, as determined from an online survey, reached its peak (15.5%) between December 19 and 21, 2022, with an estimated 82.4% of individuals in China being infected as of February 7, 2023. During the epidemic, the effectiveness of booster vaccinations against SARS-CoV-2 Omicron infection was found to be 49.0% within three months of vaccination and 37.9% between 3 and 6 months following vaccination. Furthermore, the vaccine effectiveness of the booster vaccination in relation to symptom prevention varied from 48.7% to 83.2% within three months and from 25.9% to 69.0% between 3 and 6 months post-booster vaccination.
What are the implications for public health practice?: The development and production of efficacious vaccines, together with prompt vaccinations or emergency vaccinations, have the potential to mitigate the epidemic's impact and safeguard public health.
Keywords: COVID-19; Case-control study; Vaccine effectiveness.
. 2023 Apr 28;5(17):369-373.
doi: 10.46234/ccdcw2023.070. Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms - China, December 2022-February 2023
Di Fu[SUP] 1 [/SUP], Guanhao He[SUP] 2 3 [/SUP], Huanlong Li[SUP] 4 [/SUP], Haomin Tan[SUP] 1 3 [/SUP], Xiaohui Ji[SUP] 1 3 [/SUP], Ziqiang Lin[SUP] 1 3 [/SUP], Jianxiong Hu[SUP] 1 3 [/SUP], Tao Liu[SUP] 1 3 [/SUP], Jianpeng Xiao[SUP] 5 [/SUP], Xiaofeng Liang[SUP] 2 3 [/SUP], Wenjun Ma[SUP] 1 3 [/SUP]
Affiliations
- PMID: 37197449
- PMCID: PMC10184382
- DOI: 10.46234/ccdcw2023.070
What is already known about this topic?: A considerable percentage of the population has received both primary and booster vaccinations, which could potentially provide protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infections and related symptoms.
What is added by this report?: The self-reported infection rate, as determined from an online survey, reached its peak (15.5%) between December 19 and 21, 2022, with an estimated 82.4% of individuals in China being infected as of February 7, 2023. During the epidemic, the effectiveness of booster vaccinations against SARS-CoV-2 Omicron infection was found to be 49.0% within three months of vaccination and 37.9% between 3 and 6 months following vaccination. Furthermore, the vaccine effectiveness of the booster vaccination in relation to symptom prevention varied from 48.7% to 83.2% within three months and from 25.9% to 69.0% between 3 and 6 months post-booster vaccination.
What are the implications for public health practice?: The development and production of efficacious vaccines, together with prompt vaccinations or emergency vaccinations, have the potential to mitigate the epidemic's impact and safeguard public health.
Keywords: COVID-19; Case-control study; Vaccine effectiveness.